368 related articles for article (PubMed ID: 24362531)
1. Effective inhibition of c-MET-mediated signaling, growth and migration of ovarian cancer cells is influenced by the ovarian tissue microenvironment.
Kwon Y; Smith BD; Zhou Y; Kaufman MD; Godwin AK
Oncogene; 2015 Jan; 34(2):144-53. PubMed ID: 24362531
[TBL] [Abstract][Full Text] [Related]
2. CAF-derived HGF promotes cell proliferation and drug resistance by up-regulating the c-Met/PI3K/Akt and GRP78 signalling in ovarian cancer cells.
Deying W; Feng G; Shumei L; Hui Z; Ming L; Hongqing W
Biosci Rep; 2017 Apr; 37(2):. PubMed ID: 28258248
[TBL] [Abstract][Full Text] [Related]
3. An orally available small-molecule inhibitor of c-Met, PF-2341066, reduces tumor burden and metastasis in a preclinical model of ovarian cancer metastasis.
Zillhardt M; Christensen JG; Lengyel E
Neoplasia; 2010 Jan; 12(1):1-10. PubMed ID: 20072648
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of tumor cell growth, invasion, and metastasis by EXEL-2880 (XL880, GSK1363089), a novel inhibitor of HGF and VEGF receptor tyrosine kinases.
Qian F; Engst S; Yamaguchi K; Yu P; Won KA; Mock L; Lou T; Tan J; Li C; Tam D; Lougheed J; Yakes FM; Bentzien F; Xu W; Zaks T; Wooster R; Greshock J; Joly AH
Cancer Res; 2009 Oct; 69(20):8009-16. PubMed ID: 19808973
[TBL] [Abstract][Full Text] [Related]
5. Altiratinib Inhibits Tumor Growth, Invasion, Angiogenesis, and Microenvironment-Mediated Drug Resistance via Balanced Inhibition of MET, TIE2, and VEGFR2.
Smith BD; Kaufman MD; Leary CB; Turner BA; Wise SC; Ahn YM; Booth RJ; Caldwell TM; Ensinger CL; Hood MM; Lu WP; Patt TW; Patt WC; Rutkoski TJ; Samarakoon T; Telikepalli H; Vogeti L; Vogeti S; Yates KM; Chun L; Stewart LJ; Clare M; Flynn DL
Mol Cancer Ther; 2015 Sep; 14(9):2023-34. PubMed ID: 26285778
[TBL] [Abstract][Full Text] [Related]
6. HGF and c-Met participate in paracrine tumorigenic pathways in head and neck squamous cell cancer.
Knowles LM; Stabile LP; Egloff AM; Rothstein ME; Thomas SM; Gubish CT; Lerner EC; Seethala RR; Suzuki S; Quesnelle KM; Morgan S; Ferris RL; Grandis JR; Siegfried JM
Clin Cancer Res; 2009 Jun; 15(11):3740-50. PubMed ID: 19470725
[TBL] [Abstract][Full Text] [Related]
7. YYB-101, a Humanized Antihepatocyte Growth Factor Monoclonal Antibody, Inhibits Ovarian Cancer Cell Motility and Proliferation.
Kim HJ; Heo K
Anticancer Res; 2021 Feb; 41(2):671-678. PubMed ID: 33517271
[TBL] [Abstract][Full Text] [Related]
8. Paracrine activation of MET promotes peritoneal carcinomatosis in scirrhous gastric cancer.
Zhao L; Yasumoto K; Kawashima A; Nakagawa T; Takeuchi S; Yamada T; Matsumoto K; Yonekura K; Yoshie O; Yano S
Cancer Sci; 2013 Dec; 104(12):1640-6. PubMed ID: 24118504
[TBL] [Abstract][Full Text] [Related]
9. Foretinib (GSK1363089), an orally available multikinase inhibitor of c-Met and VEGFR-2, blocks proliferation, induces anoikis, and impairs ovarian cancer metastasis.
Zillhardt M; Park SM; Romero IL; Sawada K; Montag A; Krausz T; Yamada SD; Peter ME; Lengyel E
Clin Cancer Res; 2011 Jun; 17(12):4042-51. PubMed ID: 21551255
[TBL] [Abstract][Full Text] [Related]
10. Lenvatinib in combination with golvatinib overcomes hepatocyte growth factor pathway-induced resistance to vascular endothelial growth factor receptor inhibitor.
Nakagawa T; Matsushima T; Kawano S; Nakazawa Y; Kato Y; Adachi Y; Abe T; Semba T; Yokoi A; Matsui J; Tsuruoka A; Funahashi Y
Cancer Sci; 2014 Jun; 105(6):723-30. PubMed ID: 24689876
[TBL] [Abstract][Full Text] [Related]
11. Met tyrosine kinase inhibitor, PF-2341066, suppresses growth and invasion of nasopharyngeal carcinoma.
Zhao Y; Zhang J; Tian Y; Xue C; Hu Z; Zhang L
Drug Des Devel Ther; 2015; 9():4897-907. PubMed ID: 26345996
[TBL] [Abstract][Full Text] [Related]
12. BMS-777607, a small-molecule met kinase inhibitor, suppresses hepatocyte growth factor-stimulated prostate cancer metastatic phenotype in vitro.
Dai Y; Siemann DW
Mol Cancer Ther; 2010 Jun; 9(6):1554-61. PubMed ID: 20515943
[TBL] [Abstract][Full Text] [Related]
13. Fibroblast-secreted hepatocyte growth factor mediates epidermal growth factor receptor tyrosine kinase inhibitor resistance in triple-negative breast cancers through paracrine activation of Met.
Mueller KL; Madden JM; Zoratti GL; Kuperwasser C; List K; Boerner JL
Breast Cancer Res; 2012 Jul; 14(4):R104. PubMed ID: 22788954
[TBL] [Abstract][Full Text] [Related]
14. The HGF inhibitory peptide HGP-1 displays promising in vitro and in vivo efficacy for targeted cancer therapy.
Chen L; Li C; Zhu Y
Oncotarget; 2015 Oct; 6(30):30088-101. PubMed ID: 26254225
[TBL] [Abstract][Full Text] [Related]
15. Constitutively active c-Met kinase in PC-3 cells is autocrine-independent and can be blocked by the Met kinase inhibitor BMS-777607.
Dai Y; Siemann DW
BMC Cancer; 2012 May; 12():198. PubMed ID: 22639908
[TBL] [Abstract][Full Text] [Related]
16. C7 peptide inhibits hepatocellular carcinoma metastasis by targeting the HGF/c-Met signaling pathway.
Zhao M; Wang Y; Liu Y; Zhang W; Liu Y; Yang X; Cao Y; Wang S
Cancer Biol Ther; 2019; 20(12):1430-1442. PubMed ID: 31441380
[TBL] [Abstract][Full Text] [Related]
17. Cyr61 mediates hepatocyte growth factor-dependent tumor cell growth, migration, and Akt activation.
Goodwin CR; Lal B; Zhou X; Ho S; Xia S; Taeger A; Murray J; Laterra J
Cancer Res; 2010 Apr; 70(7):2932-41. PubMed ID: 20233866
[TBL] [Abstract][Full Text] [Related]
18. Nicotine Reduces Survival via Augmentation of Paracrine HGF-MET Signaling in the Pancreatic Cancer Microenvironment.
Delitto D; Zhang D; Han S; Black BS; Knowlton AE; Vlada AC; Sarosi GA; Behrns KE; Thomas RM; Lu X; Liu C; George TJ; Hughes SJ; Wallet SM; Trevino JG
Clin Cancer Res; 2016 Apr; 22(7):1787-99. PubMed ID: 26667487
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of pro-HGF activation by SRI31215, a novel approach to block oncogenic HGF/MET signaling.
Owusu BY; Bansal N; Venukadasula PK; Ross LJ; Messick TE; Goel S; Galemmo RA; Klampfer L
Oncotarget; 2016 May; 7(20):29492-506. PubMed ID: 27121052
[TBL] [Abstract][Full Text] [Related]
20. Hepatocyte growth factor/MET in cancer progression and biomarker discovery.
Matsumoto K; Umitsu M; De Silva DM; Roy A; Bottaro DP
Cancer Sci; 2017 Mar; 108(3):296-307. PubMed ID: 28064454
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
